RECIST revisited: a review of validation studies on tumour assessment.
about
Role of positron emission tomography-computed tomography in non-small cell lung cancerTherapeutic cancer vaccines: past, present, and futureImaging-based tumor treatment response evaluation: review of conventional, new, and emerging conceptsIn vivo imaging of therapy-induced anti-cancer immune responses in humans.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Cytokine plasma levels: reliable predictors for radiation pneumonitis?Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187.Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysisPET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Response Evaluation of Chemotherapy for Lung Cancer.Image-guided local delivery strategies enhance therapeutic nanoparticle uptake in solid tumorsRECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms.Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.Preclinical multimodality phantom design for quality assurance of tumor size measurementHepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinomaRadiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PETTumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateTumor volume as an alternative response measurement for imatinib treated GIST patients.Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapyPrecision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trialNHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceTherapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI.EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival.Automated tumor volumetry using computer-aided image segmentation.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT
P2860
Q26750666-0FE84F06-9078-44C7-85E8-79DA357A7DADQ26863283-CA4AC33E-C970-4328-A5D8-A536F641610CQ26863654-31F903FE-5CE8-4937-8F87-CE97B7C39DEFQ27693338-6DED3AD4-3C59-4368-8E98-E7ED206873ACQ30651792-819A2D65-3BF4-473F-98E9-1F17E1581692Q33358117-47602EFF-5B5B-4C12-A9CA-952568B384FBQ33399928-5A4CA921-CDB3-419F-BCBB-C1A82DB110C8Q33431474-7CEFEC0C-45F5-41DE-AE4F-762FF9F697CFQ33441947-848A13D2-9E9A-4B33-8A72-6FE91320129CQ33517102-EA50195D-F9C0-4BA9-84EB-620CADFBE340Q33561602-14A98902-7EF1-4D15-842D-F742AB062DCBQ33567345-CB834246-BF30-4F8C-9026-F6E39366CE3BQ33576048-CC61DD40-07CC-4567-8EFF-0542D8104A06Q33857343-ADD55831-3FA9-4459-AE1D-D68BD4A836B3Q33898515-3583819C-201C-4666-A2C6-30E610306421Q33927990-918DDF6E-88BD-4F2E-9DD1-18CE538B7CAAQ34035194-2FDCF97A-4615-4E46-BAF8-B787A236A768Q34131801-96BF1349-D318-41EC-B350-E65591027AF6Q34202396-F42563EC-A5FC-49F9-BC75-70820D18DED5Q34217671-F3CCB9D3-23E7-4ADC-967A-B651625DB5F6Q34235986-A40AF2BD-25BC-4500-85CC-9AFACB364F5CQ34441837-605291B8-8A05-43AA-A1C7-8B64997F6134Q34469701-4EA3D3AA-A1E3-4F6F-856B-8785FC3D291BQ34475469-B27EC66A-11BC-4187-99CA-F3D70159F817Q34623728-B300133C-CDD3-419C-9238-15E382BDB32FQ34636081-196CB39C-E521-4755-BE3B-87D4FFDB7F68Q34978457-6B370148-4F30-4919-B5A0-B415F16007D4Q34998414-03699C12-9906-4D9C-9FB5-9BBA8FDD4A36Q35039508-A2326959-F1A8-497B-8BD6-F03EDAA7225CQ35046474-0D13AD1E-CF27-4862-8B7B-3ECA3097918AQ35059990-7C7864BE-1E77-474A-8999-93FC56F2F561Q35095985-3406AABA-37F1-46EB-BC19-2F14DCE41ED8Q35120054-EE328418-1FFA-4B27-8943-FF1AAC1C988DQ35148900-55980114-2EBE-4023-A490-5BE1156B244AQ35234491-FED7020A-9460-4113-A729-7C1FD14225D7Q35252217-17BBC8E5-8BD2-406A-9AFA-0522CA56B2F5Q35268118-24CF818A-BFAA-4A99-A0F6-EE7435E0A865Q35395620-729AB8F0-522B-43C8-A733-79EFBC4E94E8Q35584269-14F0D6E9-A8F6-4C17-9378-E1E3B7DA4CB9Q35591793-97DB86C3-456C-4AB7-B4FA-D1734F80A091
P2860
RECIST revisited: a review of validation studies on tumour assessment.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
RECIST revisited: a review of validation studies on tumour assessment.
@ast
RECIST revisited: a review of validation studies on tumour assessment.
@en
RECIST revisited: a review of validation studies on tumour assessment.
@nl
type
label
RECIST revisited: a review of validation studies on tumour assessment.
@ast
RECIST revisited: a review of validation studies on tumour assessment.
@en
RECIST revisited: a review of validation studies on tumour assessment.
@nl
prefLabel
RECIST revisited: a review of validation studies on tumour assessment.
@ast
RECIST revisited: a review of validation studies on tumour assessment.
@en
RECIST revisited: a review of validation studies on tumour assessment.
@nl
P2093
P1476
RECIST revisited: a review of validation studies on tumour assessment.
@en
P2093
Eisenhauer EA
Therasse P
P304
P356
10.1016/J.EJCA.2006.01.026
P577
2006-04-17T00:00:00Z